Clinical Trials
667
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (305 trials with phase data)• Click on a phase to view related trials
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
- Conditions
- Epileptic Encephalopathy
- Interventions
- Drug: S230815- Starting dose ADrug: S230815- Dose BDrug: S230815- Dose CDrug: S230815- Dose D
- First Posted Date
- 2025-11-13
- Last Posted Date
- 2025-11-13
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 20
- Registration Number
- NCT07227857
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Conditions
- Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 52
- Registration Number
- NCT06501625
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇧🇷Hospital de Amor - Barretos, Barretos, Brazil
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
- Conditions
- IDH2-mutant GliomaIDH1-mutant Glioma
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-11-06
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 42
- Registration Number
- NCT06478212
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco (UCSF) School of Medicine, San Francisco, California, United States
🇺🇸University of Miami, Miami, Florida, United States
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Conditions
- Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 48
- Registration Number
- NCT06465953
- Locations
- 🇺🇸
Presbyterian / St. Luke'S Medical Center, Denver, Colorado, United States
🇺🇸University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Drug: LLV (levoisomer form of leucovorin)Drug: 5- FU (5-Fluorouracil)
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 41
- Registration Number
- NCT06225999
- Locations
- 🇯🇵
National Cancer Center Hospital East (003), Kashiwa, Chiba, Japan
🇯🇵Chiba University Hospital (015), Chiba, Japan
🇯🇵Chiba Cancer Center (011), Chiba, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next